These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21343397)

  • 21. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and family history of cancer in women who have breast cancer.
    Lehrer S; Lee P; Tartter P; Shank B; Brower ST
    Mt Sinai J Med; 1995 Nov; 62(6):415-8. PubMed ID: 8692153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients.
    Gebhardt F; Zänker KS; Brandt B
    Biochem Biophys Res Commun; 1998 Jun; 247(2):319-23. PubMed ID: 9642124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical validation of a customized multiple signature microarray for breast cancer.
    Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
    Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation.
    García-Castillo J; Pedersen K; Angelini PD; Bech-Serra JJ; Colomé N; Cunningham MP; Parra-Palau JL; Canals F; Baselga J; Arribas J
    J Biol Chem; 2009 Sep; 284(37):25302-13. PubMed ID: 19589785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform.
    Dorraji E; Borgen E; Segura-Peña D; Rawat P; Smorodina E; Dunn C; Greiff V; Sekulić N; Russnes H; Kyte JA
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression.
    Acharyya S
    Breast Cancer Res; 2013 Apr; 15(2):309. PubMed ID: 23634980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological models of breast cancer: one size does not fit all.
    Choong LY; Lim YP
    Expert Rev Proteomics; 2011 Feb; 8(1):5-7. PubMed ID: 21329423
    [No Abstract]   [Full Text] [Related]  

  • 31. Expression of the oxytocin receptor in clinical human breast cancer tissues.
    Ito I; Kimura T; Wakasugi E; Takeda T; Kobayashi T; Shimano T; Kubota Y; Makino Y; Azuma C; Saji F
    Adv Exp Med Biol; 1995; 395():555-6. PubMed ID: 8714019
    [No Abstract]   [Full Text] [Related]  

  • 32. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.
    Pupa SM; Ligorio F; Cancila V; Franceschini A; Tripodo C; Vernieri C; Castagnoli L
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA.
    Godfrey JD; Hejazi D; Du X; Wei C; Rao E; Gomez CM
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays.
    Dixon AS; Kim SJ; Baumgartner BK; Krippner S; Owen SC
    Sci Rep; 2017 Aug; 7(1):8186. PubMed ID: 28811487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tural D; Serdengecti S; Demirelli F; Oztürk T; Ilvan S; Turna H; Ozgüroglu M; Büyükünal E
    Br J Cancer; 2014 Jun; 110(12):2996. PubMed ID: 24919019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors.
    Hutchinson L
    Nat Rev Clin Oncol; 2010 Jul; 7(7):358. PubMed ID: 20614563
    [No Abstract]   [Full Text] [Related]  

  • 37. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate?
    Kocar M; Bozkurtlar E; Telli F; Yumuk F; Kaya H; Kocar H; Serdar Turhal N
    J BUON; 2014; 19(1):245-9. PubMed ID: 24659671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
    Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.